Current status and future perspectives on treatment of liver metastasis in colorectal cancer (Review)

Mahdi Hussain Al Bandar, Nam Kyu Kim

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

Liver metastasis is the most common site of colorectal cancer (CRC) metastasis. Approximately half of all colorectal cancer patients will develop liver metastases. Although radical surgery is the standard treatment modality, only 10-20% of patients are deemed eligible for resection. Despite advances in survival with chemotherapy, surgical resection is still considered the only curative option for patients with liver metastases. Much effort has been expended to address patients with metastatic liver disease. The majority of evidence stated a significant survival benefit with surgical resection to reach an overall 5-year survival rate of 35-55% after hepatic resection. However, still majority of patients will experience disease recurrence even after a successful resection. In this review, we describe current status and controversies related to treatment options for CRC liver metastases and its potential for enhancing oncologic outcomes and improving quality of life.

Original languageEnglish
Pages (from-to)2553-2564
Number of pages12
JournalOncology Reports
Volume37
Issue number5
DOIs
Publication statusPublished - 2017 May

Fingerprint

Colorectal Neoplasms
Neoplasm Metastasis
Liver
Therapeutics
Survival
Liver Neoplasms
Liver Diseases
Survival Rate
Quality of Life
Recurrence
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{ba98878829f4459ba7aecf04fcd42da2,
title = "Current status and future perspectives on treatment of liver metastasis in colorectal cancer (Review)",
abstract = "Liver metastasis is the most common site of colorectal cancer (CRC) metastasis. Approximately half of all colorectal cancer patients will develop liver metastases. Although radical surgery is the standard treatment modality, only 10-20{\%} of patients are deemed eligible for resection. Despite advances in survival with chemotherapy, surgical resection is still considered the only curative option for patients with liver metastases. Much effort has been expended to address patients with metastatic liver disease. The majority of evidence stated a significant survival benefit with surgical resection to reach an overall 5-year survival rate of 35-55{\%} after hepatic resection. However, still majority of patients will experience disease recurrence even after a successful resection. In this review, we describe current status and controversies related to treatment options for CRC liver metastases and its potential for enhancing oncologic outcomes and improving quality of life.",
author = "{Al Bandar}, {Mahdi Hussain} and Kim, {Nam Kyu}",
year = "2017",
month = "5",
doi = "10.3892/or.2017.5531",
language = "English",
volume = "37",
pages = "2553--2564",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "5",

}

Current status and future perspectives on treatment of liver metastasis in colorectal cancer (Review). / Al Bandar, Mahdi Hussain; Kim, Nam Kyu.

In: Oncology Reports, Vol. 37, No. 5, 05.2017, p. 2553-2564.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Current status and future perspectives on treatment of liver metastasis in colorectal cancer (Review)

AU - Al Bandar, Mahdi Hussain

AU - Kim, Nam Kyu

PY - 2017/5

Y1 - 2017/5

N2 - Liver metastasis is the most common site of colorectal cancer (CRC) metastasis. Approximately half of all colorectal cancer patients will develop liver metastases. Although radical surgery is the standard treatment modality, only 10-20% of patients are deemed eligible for resection. Despite advances in survival with chemotherapy, surgical resection is still considered the only curative option for patients with liver metastases. Much effort has been expended to address patients with metastatic liver disease. The majority of evidence stated a significant survival benefit with surgical resection to reach an overall 5-year survival rate of 35-55% after hepatic resection. However, still majority of patients will experience disease recurrence even after a successful resection. In this review, we describe current status and controversies related to treatment options for CRC liver metastases and its potential for enhancing oncologic outcomes and improving quality of life.

AB - Liver metastasis is the most common site of colorectal cancer (CRC) metastasis. Approximately half of all colorectal cancer patients will develop liver metastases. Although radical surgery is the standard treatment modality, only 10-20% of patients are deemed eligible for resection. Despite advances in survival with chemotherapy, surgical resection is still considered the only curative option for patients with liver metastases. Much effort has been expended to address patients with metastatic liver disease. The majority of evidence stated a significant survival benefit with surgical resection to reach an overall 5-year survival rate of 35-55% after hepatic resection. However, still majority of patients will experience disease recurrence even after a successful resection. In this review, we describe current status and controversies related to treatment options for CRC liver metastases and its potential for enhancing oncologic outcomes and improving quality of life.

UR - http://www.scopus.com/inward/record.url?scp=85018639121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018639121&partnerID=8YFLogxK

U2 - 10.3892/or.2017.5531

DO - 10.3892/or.2017.5531

M3 - Review article

C2 - 28350137

AN - SCOPUS:85018639121

VL - 37

SP - 2553

EP - 2564

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 5

ER -